Profile data is unavailable for this security.
About the company
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
- Revenue in USD (TTM)15.43bn
- Net income in USD54.70m
- Incorporated2019
- Employees38.00k
- LocationViatris Inc1000 Mylan BoulevardCANONSBURG 15317United StatesUSA
- Phone+1 (724) 514-1800
- Fax+1 (302) 655-5049
- Websitehttps://www.viatris.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repligen Corp | 638.76m | 41.58m | 9.56bn | 1.78k | 237.65 | 4.85 | 87.21 | 14.97 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| BIO-TECHNE Corp | 1.14bn | 224.12m | 10.01bn | 3.05k | 45.94 | 5.10 | 29.94 | 8.74 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Catalent Inc | 4.10bn | -1.30bn | 10.14bn | 17.80k | -- | 2.75 | -- | 2.47 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Sarepta Therapeutics Inc | 1.24bn | -535.98m | 10.99bn | 1.31k | -- | 12.77 | -- | 8.84 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Natera Inc | 1.08bn | -434.80m | 10.99bn | 3.28k | -- | 14.22 | -- | 10.16 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| United Therapeutics Corporation | 2.33bn | 984.80m | 11.03bn | 1.17k | 11.83 | 1.84 | 10.63 | 4.74 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 11.53bn | 6.50k | -- | 3.66 | 4,689.98 | 4.61 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Incyte Corp | 3.70bn | 597.60m | 11.60bn | 2.52k | 19.54 | 2.23 | 17.05 | 3.14 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.37bn | 20.00k | 26.02 | 3.43 | 15.57 | 3.00 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 1.96bn | 312.37m | 12.61bn | 5.90k | 41.48 | 18.74 | 37.12 | 6.43 | 9.82 | 9.82 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | -- | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Viatris Inc | 15.43bn | 54.70m | 13.49bn | 38.00k | 268.37 | 0.6665 | 4.83 | 0.8745 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 14.09bn | 1.40k | 57.62 | 6.19 | 51.99 | 7.47 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Data as of Apr 24 2024. Currency figures normalised to Viatris Inc's reporting currency: US Dollar USD
40.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 136.88m | 11.53% |
| Davis Selected Advisers LPas of 31 Dec 2023 | 62.66m | 5.28% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 62.11m | 5.23% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 61.92m | 5.21% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 47.81m | 4.03% |
| Geode Capital Management LLCas of 31 Dec 2023 | 27.50m | 2.32% |
| Invesco Capital Management LLCas of 31 Dec 2023 | 26.61m | 2.24% |
| Pacer Advisors, Inc.as of 31 Dec 2023 | 20.85m | 1.76% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 20.28m | 1.71% |
| Camber Capital Management LPas of 31 Dec 2023 | 18.50m | 1.56% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
